NEW YORK (GenomeWeb News) – TTP LabTech has sold a microplate cytometer to Cancer Research UK for an RNAi-based whole-genome screening program aimed at identifying cytotoxic survival regulators.
Cancer Research UK’s London Research Institute will use the Acumen eX3 cytometer at a new high-throughput screening facility that will provide researchers with access to genome-wide siRNA and RNAi screening technologies. TTP said the Acumen X3 can help to speed genome screening time, and that it can read a 384-well plate in less than ten minutes.
The research techniques at the LRI are used in a broad range of research areas, “from yeast to flies to human cells,” the company said. The institute’s research includes studies of signaling processes that can control the intrinsic properties of cancer cells and their interactions with hosts as well as how the genome holds its integrity through environmental and endogenous changes.
Financial terms of the agreement were not released.